4151 and KNBWY Related Headlines
Go Back- First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
- First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies
- Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
- Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
- Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation at American Academy of Dermatology 2024 Meeting
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
- New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life
- Kyowa Kirin Presents Real-World Findings at ASBMR Annual Meeting Highlighting Progressive Disease Burden of X-linked Hypophosphatemia (XLH)
- Kyowa Kirin to Present New Research on X-linked Hypophosphatemia (XLH) at ASBMR Annual Meeting
- Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
- Kyowa Kirin to Acquire Orchard Therapeutics
- Kyowa Kirin Announces Acceptance for Presentations at the European Academy of Dermatology and Venereology Congress 2023
- Ardelyx (ARDX) Announces Tenapanor for Hyperphosphatemia Approved in Japan
- Tenapanor for Hyperphosphatemia Approved in Japan
- Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
- Kyowa Kirin Designs New North American Headquarters to Accelerate Innovation, Collaboration, Culture
- Kyowa Kirin Appoints Gunnar F. Kaufmann, Ph.D., as Chief Research Officer, North America
- Kyowa Kirin Launches Effort to Educate Healthcare Providers on Blood Involvement in Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin Presents New Findings from Real-World Study in Parkinson's Disease at the 2023 IAPRD Conference
- Kyowa Kirin North America Assumes Commercial Leadership Role for CRYSVITA® (burosumab-twza) Injection in North America
4151 and KNBWY Related Press Releases
Go Back- First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
- First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies
- Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
- Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
- Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation at American Academy of Dermatology 2024 Meeting
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
- New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life
- Kyowa Kirin Presents Real-World Findings at ASBMR Annual Meeting Highlighting Progressive Disease Burden of X-linked Hypophosphatemia (XLH)
- Kyowa Kirin to Present New Research on X-linked Hypophosphatemia (XLH) at ASBMR Annual Meeting
- Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
- Kyowa Kirin to Acquire Orchard Therapeutics
- Kyowa Kirin Announces Acceptance for Presentations at the European Academy of Dermatology and Venereology Congress 2023
- Tenapanor for Hyperphosphatemia Approved in Japan
- Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
- Kyowa Kirin Designs New North American Headquarters to Accelerate Innovation, Collaboration, Culture
- Kyowa Kirin Appoints Gunnar F. Kaufmann, Ph.D., as Chief Research Officer, North America
- Kyowa Kirin Launches Effort to Educate Healthcare Providers on Blood Involvement in Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin Presents New Findings from Real-World Study in Parkinson's Disease at the 2023 IAPRD Conference
- Kyowa Kirin North America Assumes Commercial Leadership Role for CRYSVITA® (burosumab-twza) Injection in North America
